Navigation Links
IFC to Invest About Rs.3 Billion in Max Healthcare

International Finance Corp. (IFC), the private sector division of World Bank, Monday announced its plans to invest Rs.3 billion in India's Max Healthcare Institute for its expansion plans.

Max Healthcare Institute is a subsidiary of Max India, a multi-business company with interests in life insurance, health care, clinical research, and specialty plastics.

"While the government is focusing its resources on increasing services to the rural areas, it is critical for the private sector to complement the public sector by expanding access to meet the demand," Guy Ellena, IFC director for health and education, said in a statement here.

The proposed expansion will add 452 beds to Max Healthcare's existing 765-bed capacity in its hospitals. It will also include adding 268 beds to its Patparganj unit here; a new 100-bed secondary and tertiary hospital in Dehradun; and an 84-bed tertiary hospital focused on obstetrics, gynaecology, and paediatrics at its Saket branch in south Delhi.

The project is also expected to create 4,500 jobs in the medical industry during the construction phase.

"Max Healthcare is proud to partner with IFC. This partnership recognizes our efforts to establish benchmarks of medical excellence and outstanding quality of service," said Max India chairman Analjit Singh.

"IFC's investment will help us realize our vision of emerging as one of India's leading healthcare providers," Singh added.

IFC, which supports private sector-led development through direct investment to promote growth, has invested over 400 million dollars in various projects across India in the 2005-06 fiscal.


'"/>




Page: 1

Related medicine news :

1. Invest on gym memberships
2. Investigations That Help Detect Lung Disease
3. Sitagliptin, Under Investigation For Type 2 Diabetes
4. China Doubles Its Investment In AIDS/HIV Treatment.
5. Biocon To Raise Its Investment In Scotland
6. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
7. President Bush Urges Citizens to Invest In Health Savings Account (HSAs)
8. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
9. Legionnaires Investigation in Chatswoods Shopping Area
10. New Multi-functional Sensing Tool To Investigate Cystic Fibrosis
11. Investigation to identify the source of HIV infection
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: IFC Invest About Billion Max Healthcare

(Date:10/6/2008)...-- Today, PARI Pharma GmbH will,unveil a prototype...ngle,dose ampoules to control medication used in t...it-dose ampoule that is required to operate the,ne...meets an unmet need by,reducing the risk of using ...ifying filling procedures, improving dose uniformi...
(Date:10/6/2008)...s presented at the American College of Gastroenter...Fla., demonstrated that TAK-390MR resulted in high...with more severe grades of erosive esophagitis (EE...Delayed Release (DDR) formulation, designed to pro...ration of acid suppression. , "These data are e...
(Date:10/6/2008)...ial supplement of the Oct. 15,journal Cancer for t...le-income countries to implement breast cancer pro...among women worldwide., "Guidelines for Internati...tion" developed by the Breast Health Global Initia...llocation -- based on countries,overall economic ...
(Date:10/6/2008)... organizers of Informex are,delighted to announce ...the,Pharmaceutical Industry, taking place November...ersey USA., The conference is chaired by David Ki...cil, and boasts an unparalleled panel of key indus...son, Bristol Myers Squibb,Genentech, Boehringer I...
Breaking Medicine News(10 mins):Health News:PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference 2Health News:Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2
...tes inflammation according to scientists. Inflamma...rs, including cancer, cardiovascular disease, diab...John Blangero, Ph.D. and senior author of the stud...ase involves an inflammation component,” The resea...
... the spot light following ace cricketer Sachin Ten...ut the condition. However, the condition is not un...teral epicondylitis as it is called in medical par...r part of the elbow becomes painful and tender, us...
...nd that it is better to insert drug-coated stents ...ple who have diabetes//. The study author Dr. Man...s University Hospital in Madrid said that the resu... diabetics are known to have poorer prognosis as c...
...be capable of altering the emotional state of huma...ential oils have been acknowledged in folk medicin...avender fragrances have been particularly attribut...matherapists. Recently a study, published in the S...
Other Medicine News:Health News:Tennis elbow not new among cricketers, say experts 2Health News:Aromatherapy: Ambient odors of orange and lavender reduce anxiety 2
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
(Date:10/7/2008)...trolled Phase II Study Shows Statisticall...N VIEW, California, October 7 /- BN,I...se II data from the,therapeutic prostate cancer va...d as part of the recently entered partnership with...The results from the Phase II prospective randomiz...
(Date:10/7/2008)...for Use on the GeneXpert(R) ...wswire-FirstCall/ -- Cepheid (Nasdaq:,CPHD) today ...European CE,IVD Mark product under the European Di...e test delivers rapid detection of vanA and/or van...ancomycin-resistant,enterococci (VRE) -- one of th...
(Date:10/6/2008)...ll/ -- Pharmasset, Inc.,(Nasdaq: VRUS ) announces...mpany as Vice President of Investor Relations and ...sible for all investor relations,functions and wil...Leutzinger., Most recently, Dr. Smith was a Vice ...rgan Securities, and has been an analyst in the se...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 1Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 2Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 3Circulation Publishes MERLIN TIMI 36 Data Showing Safety and Anti Arrhythmic Effects of Ranexa 28R 29 364 4Inquiring minds want to know about cotton fleahoppers 252 1Inquiring minds want to know about cotton fleahoppers 252 2Inquiring minds want to know about cotton fleahoppers 252 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 1Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First Line Therapy for Non Small Cell Lung Cancer 361 4Saflink and IdentiPHI Announce Merger Agreement 251 1Saflink and IdentiPHI Announce Merger Agreement 251 2Saflink and IdentiPHI Announce Merger Agreement 251 3Saflink and IdentiPHI Announce Merger Agreement 251 4Saflink and IdentiPHI Announce Merger Agreement 251 5
...NESS WIRE)--Apr 3, 2007 -,Icagen, Inc. (NASDAQ: IC...ng of the independent Data Monitoring Committee,("...formerly,ICA-17043) for the treatment of sickle ce... trial be terminated because of the low,probabilit...mary,endpoint. In making their recommendation, the...
...Newswire-FirstCall/ --,SuperGen Inc. announced tod... American Association for Cancer Research,Annual M...tations,will focus on data concerning many of Supe...d tyrosine kinase inhibitor compound,MP470 and it...olved,in cancer cell drug resistance. Presentation...
Other Medicine Technology:Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 2SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 4
Ohl periosteal elevators.
Seldin periosteal elevators.
Alexander periosteal elevators.
Langebeck periosteal elevators.
Medicine Products: